CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8,314 enrolled
Drug / intervention
Endeavor Zotarolimus Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00623441
NCT00623441N/ACompleted
CompareCT.gov

E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry

Medtronic Cardiac Rhythm and Heart Failure·observational·Posted Feb 26, 2008·Updated Nov 23, 2015

In Brief

An observational study evaluating Endeavor Zotarolimus Eluting Coronary Stent for Coronary Artery Disease. Completed, enrolled 8,314 participants.

Detailed Summary

The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis. This prospective multi-center study has been initiated: * To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation. * To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 26, 2008
Enrollment StartSep 1, 2005
Primary CompletionNov 1, 2007
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.3 years ago

Interventions

Endeavor Zotarolimus Eluting Coronary Stentdevice

Drug eluting stent